Dr. sc. hum. Thomas Muley

Education and Training

Thomas Muley is heading the Lung Biobank Heidelberg as well as the data management at Thoraxklinik of the University Hospital Heidelberg. Thomas Muley studied Biology at the University of Heidelberg. In 1990, he finalized his PhD at the Department of Pharmacology at Heidelberg University. Thereafter, he started his professional career as a Post-Doctoral Fellow in the Department of Clinical Chemistry and Bacteriology at the Thoraxklinik Heidelberg where he was Laboratory Manager until 1995 and subsequently a Senior Scientist in the Department of Surgery.

In 2000, Dr Muley founded the Lung Biobank Heidelberg, and in 2005, was appointed as Group Leader and Assistant Manager of the Translational Research Unit (STF) at the clinic. In 2009, Dr Muley took over responsibility for the clinical cancer registry and has been a coordinator of the platform biobanking and data management of the German Center for Lung Research (DZL) between 2011 and 2019.

Expertise

His research focuses on the identification of novel biomarkers and the clinical evaluation of known biomarkers for diagnosis, prognosis, and therapy prediction in thoracic diseases. His research network comprises local (DKFZ, EMBL, NCT), national (DZL, DKTK) and international (EU, NCI) partners. Via Lungbiobank, he has contributed materials and data for the molecular characterization of lung cancer and thymoma as part of The Cancer Genome Atlas (TCGA – NCI project). His work has also resulted in the publication of more than 200 original articles listed in Pubmed.

• Lung research
• Biobanking and data management in lung diseases
• Biomarkers for diagnosis and follow up of lung diseases

• Platform Biobank & Data Management
• Lung Cancer (LC)
• COPD

1. Kim-Wanner SZ, Assenov Y, Nair MB, Weichenhan D, Benner A, Becker N, Landwehr K, Kuner R, Sültmann H, Esteller M, Koch I, Lindner M, Meister M, Thomas M, Bieg M, Klingmueller U, Schlesner M, Warth A, Brors B, Seifried E, Bonig H, Plass C, Risch A, Muley T. Genome-wide DNA methylation profiling in early stage I lung adenocarcinoma reveals predictive aberrant methylation in the promoter region of the long non-coding RNA PLUT - an exploratory study. J Thorac Oncol. 2020 Apr 6. pii: S1556-0864(20)30287-2. doi: 10.1016/j.jtho.2020.03.023.
2. Muley T, He Y, Rolny V, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Meister M, Herth FJ, Dayyani F. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. Lung Cancer. 2019 ; 130:194-200
3. Dabral S, Muecke C, Valasarajan C, Schmoranzer M, Wietelmann A, Semenza GL, Meister M, Muley T, Seeger-Nukpezah T, Samakovlis C, Weissmann N, Grimminger F, Seeger W, Savai R, Pullamsetti SS. A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension. Nat Commun. 2019 May 13;10(1):2130.
4. Cancer Genome Atlas Research Network.Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31;511(7511):543-50
5. Muley T, Herth FJF, Schnabel P, Dienemann H, Meister M. From tissue to molecular phenotyping: Pre-analytical requirements Heidelberg Experience. Transl Lung Cancer Res 2012;1(2):111-121

PubMed Link